{"id":32182,"date":"2025-05-15T17:35:14","date_gmt":"2025-05-15T12:05:14","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32182"},"modified":"2025-05-15T17:35:15","modified_gmt":"2025-05-15T12:05:15","slug":"medtech-news-for-glucotrack-ge-healthcare-bd","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd","title":{"rendered":"Glucotrack Secures Ethical Approval for Extended Clinical Trial of Continuous Blood Glucose Monitor; GE HealthCare Announces FDA Approval for Pediatric Use of Optison and Launches New Ultra-premium 1.5T MRI System; Envoy Medical Advances to Final Stage Following Clinical Milestone; SeaStar Medical Hits Interim Enrollment Goal in NEUTRALIZE-AKI Trial; BD Unveils New Cell Analyzer Integrating Spectral and Real-Time Imaging Innovations"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fa15c492d88\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fa15c492d88\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#Glucotrack_Announced_Ethical_Approval_for_Long-Term_Clinical_Study_of_Continuous_Blood_Glucose_Monitor\" >Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#GE_HealthCare_Announced_FDA_Approval_of_Pediatric_Indication_for_Optison_Ultrasound_Enhancing_Agent\" >GE HealthCare Announced FDA Approval of Pediatric Indication for Optison Ultrasound Enhancing Agent&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#Envoy_Medical_Achieved_Clinical_Trial_Milestone_and_is_Optimistic_About_Expansion_into_the_Final_Stage_of_Trial\" >Envoy Medical Achieved Clinical Trial Milestone and is Optimistic About Expansion into the Final Stage of Trial&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#SeaStar_Medical_Reached_Interim_Enrollment_Target_for_NEUTRALIZE-AKI_Pivotal_Trial_of_SCD_Therapy_for_Adult_Patients_with_Acute_Kidney_Injury\" >SeaStar Medical Reached Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#BD_Launched_Landmark_Cell_Analyzer_Featuring_Breakthrough_Spectral_and_Real-Time_Cell_Imaging_Technologies\" >BD Launched Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\/#GE_HealthCare_Unveiled_Ultra-premium_High-performance_Gradient_15T_MRI_System\" >GE HealthCare Unveiled Ultra-premium, High-performance Gradient 1.5T MRI System&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-glucotrack-announced-ethical-approval-for-long-term-clinical-study-of-continuous-blood-glucose-monitor-nbsp\"><span class=\"ez-toc-section\" id=\"Glucotrack_Announced_Ethical_Approval_for_Long-Term_Clinical_Study_of_Continuous_Blood_Glucose_Monitor\"><\/span><strong>Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 13, 2025, Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it received ethical approval from the St. Vincent\u2019s Hospital Melbourne Human Research Ethics Committee (HREC) for its long-term clinical study of the Company\u2019s continuous blood glucose monitor (\u201cCBGM\u201d) in participants with type 1 and type 2 diabetes.<\/p>\n\n\n\n<p>The prospective, single-arm, multi-center study was set to enroll up to 30 participants with type 1 and type 2 diabetes mellitus requiring glucose monitoring and intensive insulin therapy. The study aimed to evaluate the device\u2019s performance and safety over an initial period of 1 year. The Company indicated that it might submit additional requests to extend the study to 3 years, following the completion of the initial period. With this approval, and following the Australian clinical study process, the Company proceeded to notify the Therapeutic Goods Administration (TGA), Australia\u2019s regulatory authority for therapeutic goods such as medicines, medical devices, and diagnostic tests before initiating enrollment. The first patients were expected to be implanted by July. The study was conducted under Principal Investigator Professor David O\u2019Neal (MBBS, MD, FRACP), Director and Founder of the Diabetes Technology Research Group at the University of Melbourne, Department of Medicine at St Vincent\u2019s Hospital, Melbourne, and Associate Professor Neale Cohen (MBBS, FRACP), Head of the Diabetes Clinical Research Laboratory at the Baker Heart and Diabetes Institute, Melbourne.<\/p>\n\n\n\n<p><em>\u201cI am excited to be bringing my expertise in leading clinical trials focused on novel diabetes technology to this important study of a device that directly measures blood glucose,\u201d said Professor O\u2019Neal. \u201cThis technology shows great promise for the ability to improve glycemic control and offer patients expanded choice in continuous glucose monitoring systems. The ability to directly measure glucose in blood rather than interstitial fluid could represent a significant advancement for people with diabetes seeking more accurate real-time glucose values.\u201d<\/em><\/p>\n\n\n\n<p>Glucotrack\u2019s continuous blood glucose monitoring (CBGM) System is a long-term, implantable solution designed to provide continuous and accurate blood glucose monitoring for up to three years. Unlike traditional continuous glucose monitoring (CGM) systems, which measure glucose levels from interstitial fluid, the CBGM system measures glucose directly from the blood, thereby eliminating the lag time commonly associated with interstitial readings.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\"><strong>Blood Glucose Monitoring Systems Market Report<\/strong><\/a>\u201d, the blood glucose monitoring systems market was valued at&nbsp;<strong>USD 12.12 billion<\/strong>&nbsp;in 2024, growing at a&nbsp;<strong>CAGR of 7.72%<\/strong>&nbsp;during the forecast period from&nbsp;2024 to 2030 to reach <strong>USD 18.89 billion<\/strong> by 2030. The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as&nbsp;diabetes&nbsp;and&nbsp;impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ge-healthcare-announced-fda-approval-of-pediatric-indication-for-optison-ultrasound-enhancing-agent-nbsp\"><span class=\"ez-toc-section\" id=\"GE_HealthCare_Announced_FDA_Approval_of_Pediatric_Indication_for_Optison_Ultrasound_Enhancing_Agent\"><\/span><strong>GE HealthCare Announced FDA Approval of Pediatric Indication for Optison Ultrasound Enhancing Agent&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 13, 2025, GE HealthCare announced that the U.S. Food and Drug Administration (FDA) approved a pediatric indication for its ultrasound enhancing agent (UEA), Optison\u2122 (Perflutren Protein-Type a Microspheres Injectable Suspension, USP). This approval is expected to enhance the clarity and diagnostic accuracy of echocardiograms in pediatric patients, enabling cardiologists to better assess ventricular function and identify potential heart abnormalities or diseases.<\/p>\n\n\n\n<p>Optison works by using gas-filled microbubbles that reflect ultrasound waves more effectively than surrounding tissues or blood. This improves the visualization of heart chambers and endocardial borders, crucial for evaluating cardiac conditions. With a long-established safety profile, Optison is also the only UEA currently available in the U.S. that is free of polyethylene glycol (PEG), making it a safer option for patients with PEG hypersensitivity, who may be at risk for anaphylaxis or other adverse reactions.&nbsp;<\/p>\n\n\n\n<p><em>\u201cIn some pediatric patients, standard echocardiography cannot produce sufficiently clear images of the heart, potentially hindering cardiologists\u2019 ability to accurately diagnose underlying conditions,\u201d said Jit Saini, MD, Chief Medical Officer of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare. \u201cThis regulatory approval is a significant milestone that affirms the safety and efficacy of Optison in pediatric patients of all ages and expands our ability to offer this advanced imaging solution to a broader patient population. By facilitating more accurate measurement of left ventricular function, Optison enhances diagnostic capabilities, ultimately improving patient outcomes and providing greater value to healthcare providers and their patients.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiovascular-ultrasound-system\"><strong>Cardiovascular Ultrasound System Market Report<\/strong><\/a>,\u201d the global cardiovascular ultrasound system market was valued at <strong>USD 1.61 billion<\/strong> in 2023, growing at a <strong>CAGR of 4.79%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 2.11 billion<\/strong> by 2030. The cardiovascular ultrasound system market is witnessing positive growth owing to various factors such as the rise in the geriatric population, the increasing incidence of cardiovascular diseases, the increase in sedentary lifestyles, and the rising regulatory approvals for the cardiovascular ultrasound system. Therefore, the market for cardiovascular ultrasound systems is expected to grow during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-envoy-medical-achieved-clinical-trial-milestone-and-is-optimistic-about-expansion-into-the-final-stage-of-trial-nbsp\"><span class=\"ez-toc-section\" id=\"Envoy_Medical_Achieved_Clinical_Trial_Milestone_and_is_Optimistic_About_Expansion_into_the_Final_Stage_of_Trial\"><\/span><strong>Envoy Medical Achieved Clinical Trial Milestone and is Optimistic About Expansion into the Final Stage of Trial&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 13, 2025, Envoy Medical\u00ae, Inc., a pioneering company in hearing health specializing in fully implanted hearing solutions that leverage the ear\u2019s natural anatomy, has announced a significant milestone: the successful activation of all 10 participants in the first stage of its pivotal clinical trial for the fully implanted Acclaim\u00ae Cochlear Implant.&nbsp;<\/p>\n\n\n\n<p>The Acclaim Cochlear Implant (Acclaim CI) is considered a groundbreaking advancement in hearing technology, as it is believed to be the first fully implanted cochlear implant that does not rely on external microphones. Instead, it utilizes a unique sensor that captures sound by harnessing the natural anatomy of the ear. The Acclaim CI is intended for adults with severe to profound sensorineural hearing loss who do not derive adequate benefit from conventional hearing aids. Implantation eligibility is determined by a qualified physician based on individual clinical assessments.<\/p>\n\n\n\n<p><em>Brent Lucas, CEO of Envoy Medical, commented, &#8220;We are excited to report the positive and meaningful progress of our pivotal clinical trial, which is currently on track and moving along as anticipated. We are optimistic we will be able to expand the study into the second and final stage during the fourth quarter of this year. We are also encouraged by the reported interest from people suffering from significant hearing loss who want to wait until a fully implanted cochlear implant is an option. We believe there is significant pent-up demand for fully implanted cochlear implants, and we are thrilled to be closer to meeting this unmet need.&#8221;<\/em><\/p>\n\n\n\n<p>The Esteem\u00ae fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved fully implanted* hearing device designed for adults with moderate to severe sensorineural hearing loss, offering continuous 24\/7 hearing by utilizing the ear\u2019s natural anatomy. Unlike traditional hearing aids, the Esteem implant is completely invisible, with no externally worn components and nothing placed in the ear canal for functionality. Once implanted, users do not need to put it on, take it off, clean it, or worry about losing it. The Esteem FI-AMEI provides a seamless and maintenance-free hearing experience, delivering true around-the-clock auditory support.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cochlear-implants-market\"><strong>Cochlear Implants Market Report<\/strong><\/a>,&#8221; the cochlear implants market was valued at <strong>USD 1.38 billion<\/strong> in 2023, growing at a <strong>CAGR of 9.92%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 2.43 billion<\/strong> by 2030. The cochlear implants market is observing substantial market growth primarily owing to the increasing prevalence of hearing loss &amp; incurs substantial economic costs, investing in cochlear implants &amp; improving access to these devices and supportive reimbursement policies are anticipated to further accelerate the overall growth of the cochlear implants market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-seastar-medical-reached-interim-enrollment-target-for-neutralize-aki-pivotal-trial-of-scd-therapy-for-adult-patients-with-acute-kidney-injury-nbsp\"><span class=\"ez-toc-section\" id=\"SeaStar_Medical_Reached_Interim_Enrollment_Target_for_NEUTRALIZE-AKI_Pivotal_Trial_of_SCD_Therapy_for_Adult_Patients_with_Acute_Kidney_Injury\"><\/span><strong>SeaStar Medical Reached Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 13, 2025, SeaStar Medical Holding Corporation, a commercial-stage healthcare company dedicated to advancing treatments for critically ill patients at risk of organ failure and death announced that it reached the midpoint of its NEUTRALIZE-AKI pivotal clinical trial. This milestone enables a prespecified per-protocol interim analysis to be conducted by the study\u2019s independent Data Safety Monitoring Review Board (DSMB). SeaStar Medical expects the DSMB to share its findings in the third quarter of 2025.<\/p>\n\n\n\n<p>The NEUTRALIZE-AKI trial is assessing SeaStar\u2019s Selective Cytopheretic Device (SCD) therapy as a potential treatment for adult patients with Acute Kidney Injury (AKI) who require continuous renal replacement therapy (CRRT). The interim analysis, which is blinded to all parties except the DSMB, will review safety data and validate the trial\u2019s powering assumptions based on the first 100 patients out of the planned total of 200. This analysis will be conducted after the evaluation of the trial\u2019s primary endpoint for those patients.<\/p>\n\n\n\n<p>The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device, a randomized clinical trial in acute kidney injury trial is a pivotal, randomized clinical study designed to enroll up to 200 adult patients diagnosed with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The primary endpoint of the trial is a composite measure of 90-day mortality or dialysis dependency, comparing outcomes in patients receiving the Selective Cytopheretic Device (SCD) in combination with CRRT versus those receiving CRRT alone as the standard of care. With 100 patients currently enrolled, the trial will undergo a per-protocol interim analysis focused on 90-day outcomes, as reviewed by the Data Safety Monitoring Board (DSMB).<\/p>\n\n\n\n<p>Key secondary endpoints include 28-day mortality, ICU-free days within the first 28 days, the incidence of major adverse kidney events at Day 90, and dialysis dependency at one year. The trial will also conduct subgroup analyses to evaluate the efficacy of SCD therapy in patients with AKI who are also diagnosed with sepsis or acute respiratory distress syndrome (ARDS), offering further insights into its potential benefit in critically ill populations.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/continuous-renal-replacement-therapy-machines-market\"><strong>Continuous Renal Replacement Therapy Machines (CRRT) Market Report<\/strong><\/a>\u201d, the CRRT machines market was valued at <strong>USD 1.17 billion<\/strong> in 2023, growing at a <strong>CAGR of 7.38%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 1.78 billion<\/strong> by 2030. The CRRT machines market is experiencing significant growth due to the increasing instances of acute kidney injury and sepsis, coupled with advancements in technology and product launches, which are acting as major factors contributing to the overall growth of the CRRT machines market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bd-launched-landmark-cell-analyzer-featuring-breakthrough-spectral-and-real-time-cell-imaging-technologies-nbsp\"><span class=\"ez-toc-section\" id=\"BD_Launched_Landmark_Cell_Analyzer_Featuring_Breakthrough_Spectral_and_Real-Time_Cell_Imaging_Technologies\"><\/span><strong>BD Launched Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 13, 2025, BD, a global leader in medical technology, announced the worldwide commercial launch of the BD FACSDiscover\u2122 A8 Cell Analyzer, marking a significant advancement in cellular analysis. The BD FACSDiscover\u2122 A8 is the first cell analyzer to integrate both advanced spectral flow cytometry and real-time cell imaging, providing researchers with the ability to gain deeper insights into cellular behavior with enhanced ease and throughput.<\/p>\n\n\n\n<p>At its core, the platform features two groundbreaking technologies: BD SpectralFX\u2122 Technology, which enables the simultaneous analysis of 50 or more parameters from a single cell, greatly improving resolution and sensitivity, and BD CellView\u2122 Image Technology, which allows high-speed, fluorescent, and label-free imaging at the single-cell level to capture spatial and morphological details in real time. This combination provides researchers with unprecedented visual validation and analysis capabilities, particularly valuable in fields such as novel biomarker discovery.<\/p>\n\n\n\n<p>Building on the innovations of the BD FACSDiscover\u2122 S8 Cell Sorter, which was featured on the cover of Science, the A8 Analyzer sets a new benchmark in cell analysis by offering unmatched depth, speed, and sensitivity. Tailored for translational research, key features of the A8 include high-throughput automation with walkaway capabilities, industry-leading cost-per-insight efficiency, user-friendly software workflows optimized for managing large and complex datasets, and seamless integration with the BD ecosystem, including BD FACSDiscover\u2122 Cell Sorters and BD reagents.<\/p>\n\n\n\n<p><em>&#8220;The BD FACSDiscover\u2122 A8 Cell Analyzer signals an exciting step forward for researchers in areas like immuno-oncology that require tools delivering excellent reproducibility and performance while managing budget constraints,&#8221; said Rui Gardner, head of Flow Cytometry Core Facility at Memorial Sloan Kettering Cancer Center, an early access collaboration site. &#8220;Our investigators have already learned so much using this new technology, and we look forward to performing deep immunophenotyping for high-fidelity biomarker discovery to elucidate insights that can advance research and improve human health.\u201d<\/em><\/p>\n\n\n\n<p>Together, these innovations position the BD FACSDiscover\u2122 A8 Cell Analyzer as a transformative tool for accelerating scientific discovery.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/clinical-chemistry-analyzers-market\"><strong>Clinical Chemistry Analyzers Market Report<\/strong><\/a>\u201d, the global clinical chemistry analyzers market was valued at&nbsp;<strong>USD 12.38 billion<\/strong>&nbsp;in 2021 and will grow at a&nbsp;<strong>CAGR of 4.82%<\/strong>&nbsp;during the forecast period from 2024 to 2030 to reach&nbsp;<strong>USD 16.39 billion<\/strong>&nbsp;by 2030. The clinical chemistry analyzers market is observing remarkable market growth due to factors such as the growing prevalence of chronic diseases and the rising burden of the geriatric population. Furthermore, the surging demand for early diagnosis of disease, the increasing importance and awareness of point-of-care testing, surging technological advancements in the devices along with the increasing product launches and approvals, the presence of key players in the market, and other factors will create a requisite for the clinical chemistry analyzers in the market. Therefore, the market for clinical chemistry analyzers is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ge-healthcare-unveiled-ultra-premium-high-performance-gradient-1-5t-mri-system-nbsp\"><span class=\"ez-toc-section\" id=\"GE_HealthCare_Unveiled_Ultra-premium_High-performance_Gradient_15T_MRI_System\"><\/span><strong>GE HealthCare Unveiled Ultra-premium, High-performance Gradient 1.5T MRI System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 12, 2025, GE HealthCare introduced the SIGNA\u2122 Sprint, an ultra-premium wide bore 1.5T MRI system with high-performance gradients (FDA 510(k) pending), at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025. This next-generation MRI technology is engineered to advance imaging capabilities in cardiology, oncology, and other clinical and research fields.<\/p>\n\n\n\n<p>The global demand for more sophisticated diagnostic tools continues to rise, cardiovascular disease remains the leading cause of death, responsible for 32% of global fatalities\u00b2, while cancer claims nearly 10 million lives annually\u00b3. Innovations like SIGNA Sprint are poised to make a meaningful difference by enhancing the precision and efficiency of MRI diagnostics in these critical areas.<\/p>\n\n\n\n<p>SIGNA Sprint aims to bring the high-gradient performance typically associated with 3.0T MRI systems to the more accessible 1.5T platform. Optimized for high-quality diffusion imaging\u2014a key modality in oncology for diagnosis and treatment planning it is built to empower clinicians and researchers to push the traditional limits of 1.5T imaging. This enables both accelerated clinical application and cutting-edge research.<\/p>\n\n\n\n<p><em>\u201cWe are driven to push the boundaries of what\u2019s possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response,\u201d said Kelly Londy, CEO, MR, GE HealthCare. \u201cWe are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging.\u201d<\/em><\/p>\n\n\n\n<p>Delivering a powerful 65 mT\/m amplitude and 200 T\/m\/s slew rate per axis, SIGNA Sprint supports fast imaging with outstanding clarity, enabling visualization of sub-millimetric structures. It also incorporates deep learning technologies to aid in diagnostic precision and monitoring treatment responses in oncology. The system supports the shift toward quantitative MRI, offering deeper tissue characterization and moving beyond conventional anatomical imaging. Advanced deep-learning reconstruction for cardiac imaging further enhances scan speed and interpretation, helping reduce variability and reliance on expert readers.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/magnetic-resonance-imaging-devices-market\"><strong>Magnetic Resonance Imaging (MRI) Devices Market Report<\/strong><\/a>\u201d, the magnetic resonance imaging devices market was valued at <strong>USD 8,207.06 million<\/strong> in 2024, growing at a <strong>CAGR of 6.54%<\/strong> during the forecast period from 2025 to 2032 to reach <strong>USD 13,553.33 million<\/strong> by 2032. The rising prevalence of various chronic disorders, such as cardiovascular diseases, cancer, and neurological conditions, is fueling the demand for precise diagnostic tools like MRI, which offers superior imaging capabilities for soft tissues and organs. Additionally, the increasing awareness and the emphasis on early diagnosis of chronic disease are encouraging patients and healthcare providers to adopt MRI for timely intervention. Furthermore, technological advancements play a crucial role in boosting the MRI market, with innovations such as high-field and open MRI systems, functional MRI (fMRI), and faster scan times improving the accuracy, comfort, and efficiency of the imaging process. Collectively, these factors are expected to expand the demand for magnetic resonance imaging devices globally during the forecast period from 2025 to 2032.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor&nbsp; On May 13, 2025, Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it received ethical approval from the St. Vincent\u2019s Hospital Melbourne Human Research Ethics Committee (HREC) for [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32184,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19105,19687,21130,18859,19331,2753,17021,16975],"industry":[17226],"therapeutic_areas":[17242,17236],"class_list":["post-32182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-blood-glucose-monitoring-systems","tag-cardiovascular-ultrasound-system","tag-clinical-chemistry-analyzers","tag-cochlear-implants","tag-magnetic-resonance-imaging-devices","tag-medical-device","tag-medical-devices-market","tag-medtech-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-otolaryngology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Glucotrack, GE Healthcare, BD<\/title>\n<meta name=\"description\" content=\"Glucotrack\u2019s Continuous Blood Glucose Monitor; GE HealthCare\u2019s 1.5T MRI System; Envoy Medical\u2019s Acclaim Cochlear Implant\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Glucotrack, GE Healthcare, BD\" \/>\n<meta property=\"og:description\" content=\"Glucotrack\u2019s Continuous Blood Glucose Monitor; GE HealthCare\u2019s 1.5T MRI System; Envoy Medical\u2019s Acclaim Cochlear Implant\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T12:05:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T12:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Glucotrack, GE Healthcare, BD","description":"Glucotrack\u2019s Continuous Blood Glucose Monitor; GE HealthCare\u2019s 1.5T MRI System; Envoy Medical\u2019s Acclaim Cochlear Implant","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Glucotrack, GE Healthcare, BD","og_description":"Glucotrack\u2019s Continuous Blood Glucose Monitor; GE HealthCare\u2019s 1.5T MRI System; Envoy Medical\u2019s Acclaim Cochlear Implant","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-15T12:05:14+00:00","article_modified_time":"2025-05-15T12:05:15+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd","name":"MedTech News | Glucotrack, GE Healthcare, BD","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd.png","datePublished":"2025-05-15T12:05:14+00:00","dateModified":"2025-05-15T12:05:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Glucotrack\u2019s Continuous Blood Glucose Monitor; GE HealthCare\u2019s 1.5T MRI System; Envoy Medical\u2019s Acclaim Cochlear Implant","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-glucotrack-ge-healthcare-bd#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd.png","width":772,"height":482,"caption":"medtech-news-for-glucotrack-ge-healthcare-bd"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/15173502\/medtech-news-for-glucotrack-ge-healthcare-bd-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blood Glucose Monitoring Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiovascular Ultrasound System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clinical Chemistry Analyzers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cochlear Implants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Magnetic Resonance Imaging Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Blood Glucose Monitoring Systems<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular Ultrasound System<\/span>","<span class=\"advgb-post-tax-term\">Clinical Chemistry Analyzers<\/span>","<span class=\"advgb-post-tax-term\">Cochlear Implants<\/span>","<span class=\"advgb-post-tax-term\">Magnetic Resonance Imaging Devices<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 months ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on May 15, 2025","modified":"Updated on May 15, 2025"},"absolute_dates_time":{"created":"Posted on May 15, 2025 5:35 pm","modified":"Updated on May 15, 2025 5:35 pm"},"featured_img_caption":"medtech-news-for-glucotrack-ge-healthcare-bd","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32182"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32182\/revisions"}],"predecessor-version":[{"id":32183,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32182\/revisions\/32183"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32184"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32182"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32182"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}